Actuate Therapeutics, Inc. (ACTU) Prices $11.0M Stock/Warrant Offering

Actuate Therapeutics priced a $11.0M offering of 30,985,900 shares and warrants, exercisable at $0.45, expected to close Oct. 28, 2026. The company aims to raise funds for clinical-stage biotech operations.

Original reporting
Published Oct 27, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 12:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Actuate Therapeutics, Inc. (ACTU) Prices $11.0M Stock/Warrant Offering — source image
Decision brief

The 30-second read

$ACTUBearishLow
01

Why it matters

The $11M raise provides runway but introduces dilution risk; market reaction will depend on perceived trial upside.

02

Market read

Small‑cap biotech financing event with modest price impact potential.

03

What to watch

Potential strategic investors or partnership commitments tied to the raise.

Relevance 6/10Novelty 7/10Timing: today

Background

Actuate Therapeutics is a clinical‑stage biotech seeking funds ahead of upcoming trial milestones.

Company-level read

Ticker impact

$ACTUBearishHigh confidence
Context

Actuate Therapeutics announced a public offering of ~31M shares and warrants raising $11M.

Expected impact

downward pressure as investors price in dilution

Evidence & confidence

New capital raise for a micro‑cap biotech typically depresses share price, especially with warrants at a low exercise price.

Market effects

May signal continued financing needs for clinical‑stage biotech sector.

Limited to US biotech investors.

Minimal global impact.

Counterpoint

If the capital raise funds a breakthrough trial, the stock could rally despite dilution.

Key entities

  • Actuate Therapeutics, Inc.

    Clinical‑stage biotech issuing shares and warrants.

Related articles

$ACTUMed

Actuate reports preclinical data on oral elraglusib in melanoma

Actuate Therapeutics (ACTU) reported preclinical data showing its oral drug candidate elraglusib achieved up to 77% tumor growth inhibition in a melanoma model. The company plans to initiate a Phase 1/2 clinical trial in Q1 2027, starting with refractory metastatic melanoma patients. Elraglusib has previously shown promise in a Phase 2 trial for metastatic pancreatic cancer.

$ACTUMedAI 8/10

Actuate Advances Oral Elraglusib Toward 2027 Trial Following Positive Melanoma Data

Actuate Therapeutics (ACTU) reported positive preclinical data for its oral elraglusib tablet, showing tumor growth inhibition and immune-modulating effects in a melanoma mouse model. The company plans to present the findings at the EORTC-NCI-AACR Symposium in November 2026 and initiate a Phase 1/2 clinical trial in Q1 2027. The U.S. Patent Office issued a Notice of Allowance for the oral formulation's patent.

$MARAMed

MARA prices $185M debt offering after $1.1B Bitcoin sale

MARA priced an $185M debt offering at 8.75% interest, maturing in 2032, to finance its $1.5B acquisition of Long Ridge Energy. The deal includes a 485MW power plant and land for potential data centers. MARA recently sold $1.1B in Bitcoin to repay debt. Long Ridge generated $144M in annualized adjusted EBITDA, but interest payments may consume nearly half.

$RIOLow

Rio Tinto commits US$250m to address damage from Bougainville's Panguna mine

Rio Tinto will contribute $250m to a fund addressing environmental and human rights impacts of the Panguna mine, per an agreement with Bougainville Copper Limited, the Autonomous Bougainville Government, and community leaders. The fund aims to support practical responses to identified impacts and social projects. Details will be developed in consultation with communities.